Company: CSCIF
Filing Date: 2025-04-09
Form Type: 20-F
Source: 0001641172-25-003456
Chunk: 257

Company: COSCIENS Biopharma Inc.
Filing Date: 2025-04-09
Form: 20-F
Item: Item 18
Chunk 257
---
 include restricted cash equivalents and property and equipment, and are detailed by geographical area as follows:
 
Summary of non-current assets by geographical area
 
                                                December 31,   
                     2024                   2023               
                                        $        $             
Germany                          205                  -        
Canada                         9,320                  10,979   
United States                     71                  -        
Austria                        1,493             681           
Non Current Assets            11,089                  11,660   

F-44
----
COSCIENS Biopharma Inc.
 Notes to Consolidated Financial Statements As of December 31, 2024 and 2023 and for the years ended December 31, 2024, 2023 and 2022 
(in thousands of US dollars, except share and per share data and where otherwise noted) 

26.      Commitments   
      and Contingencies
-----------------------
 
Significant expenditure contracted for at the end of the reporting period but not recognized as liabilities is as follows:
 
Schedule of expected future minimum lease payments
 
                            TOTAL      
---------------------------------------
                          $            
Less than 1 year               1,287   
1 - 3 years               34           
4 - 5 years                    -       
More than 5 years              -       
Minimum lease payments,        1,321   
net                                    
 
The Company previously entered into license agreements with Agriculture Canada (AG) for a technology to increase the concentration of avenanthramides in selected oat and with University of Alberta for a Pressurized Gaz expanded Technology (PGX) for the processing of various polymers. The royalty percentage rate would be 2% strictly for sales made from avenanthramides produced from the AG technology while royalty percentage rates would range between 1.0% to 3.5% for sales made from products manufactured using the PGX Technology, the rate being according to the classification of the resulting product (cosmeceutical, nutraceutical, pharmaceutical).
 

27.        Related     
      party disclosures
-----------------------
 
Compensation of key management
 
Key management includes the Company’s Directors, Chief Executive Officer, Chief Financial Officer, Chief Scientific Officer and Chief Medical Officer. Compensation awarded to key management is summarized as follows:
 Schedule of compensation for key management

                                                                            December 31,   
                                   2024                2023                2022            
                                                   $       $                              $
Salaries and short-term benefits           1,587               1,344                 971   
Post